Solum Healthcare, an artificial intelligence (AI) driven cancer diagnostics firm, recently showcased its latest clinical findings on non-invasive cancer detection using urine samples at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, the company announced on April 23.
The AACR Annual Meeting, the world’s largest cancer research conference, brings together researchers and healthcare professionals globally to share cutting-edge advances in cancer diagnosis and treatment.
This year’s event drew over 22,000 attendees and featured 265 clinical trial abstracts, underscoring the intense interest in cancer research.
On April 20, during the Diagnostic Biomarkers clinical research track session, Solum Healthcare presented findings from its AI-based cancer diagnosis study, which analyzed 1,240 clinical samples.
The research employed Raman spectroscopy to examine metabolite profiles in patients’ urine, combining this data with AI algorithms to identify cancer-specific patterns.
This innovative approach offers a notable advantage over traditional invasive methods like biopsies or blood tests, as it utilizes urine samples for easier data collection. The presentation highlighted the analysis of extensive clinical data as a key research outcome.
Throughout the conference, Solum Healthcare’s poster attracted international researchers and medical professionals, fostering discussions on research directions and potential collaborations. The company plans to leverage these clinical results to strategically approach global regulatory processes and market entry across various countries.
Solum Healthcare Chief Executive Officer (CEO) Kim Ji-hee remarked that its participation in AACR 2024 allowed them to share the clinical data and research findings on non-invasive cancer diagnostics with the international scientific community. It aims to expand the technology’s applications through continued research and global collaborations.
